Intas in pact with Spanish drug maker mAbxience to sell biosimilar etanercept in over 150 countries

mAbxience, a majority-owned company of German drug maker Fresenius Kabi, also has partial ownership from Insud Pharma, will be responsible for the development, manufacturing, and supply of the Etanercept biosimilar.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news